Alvotech (ALVO) Current Deferred Revenue (2020 - 2026)
Alvotech (ALVO) posted Current Deferred Revenue of $13.1 million for Q1 2026, down 56.76% on a QoQ basis from $30.4 million in Q4 2025, and down 84.91% year-over-year from $87.0 million in Q1 2025.
Alvotech (ALVO) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Alvotech's Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $13.1 million for Q1 2026.
- Quarterly Current Deferred Revenue fell 84.91% year-over-year to $13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.1 million (down 84.91% YoY) and the FY2025 annual result came in at $30.4 million, up 90.01% from the prior year.
- Current Deferred Revenue was $13.1 million for Q1 2026 at Alvotech, down from $30.4 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $132.4 million in Q4 2023 and bottomed at $13.1 million in Q1 2026.
- A 5-year average of $66.0 million and a median of $70.5 million in 2025 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue slumped 87.93% — and 2025, when it soared 90.01%.
- Alvotech's Current Deferred Revenue stood at $93.9 million in 2022, then jumped by 41.0% to $132.4 million in 2023, then slumped by 87.93% to $16.0 million in 2024, then surged by 90.01% to $30.4 million in 2025, then plunged by 56.76% to $13.1 million in 2026.
- Business Quant data shows ALVO's Current Deferred Revenue at $13.1 million in Q1 2026, $30.4 million in Q4 2025, and $80.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.13 Mn |
| Dec 31, 2025 | 30.36 Mn |
| Sep 30, 2025 | 80.72 Mn |
| Jun 30, 2025 | 60.33 Mn |
| Mar 31, 2025 | 87.00 Mn |
| Dec 31, 2024 | 15.98 Mn |
| Sep 30, 2024 | 85.50 Mn |
| Jun 30, 2024 | 90.12 Mn |
| Mar 31, 2024 | 88.91 Mn |
| Dec 31, 2023 | 132.44 Mn |
| Jun 30, 2023 | 58.98 Mn |
| Mar 31, 2023 | 54.65 Mn |
| Dec 31, 2022 | 93.93 Mn |
| Jun 30, 2022 | 32.33 Mn |
| Dec 31, 2021 | 74.54 Mn |
| Dec 31, 2020 | 53.07 Mn |